欧美在线免费看,西西大胆午夜视频无码 ,日韩高清在线观看不卡一区二区

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein therapeutics and microecological agents. We focus on pharmaceutical research in the therapeutic fields of antiviral, oncology, immunology, hematology, digestion and degenerative diseases.It has built cutting-edge biotechnology platforms such as new proteins, new antibodies and nucleic acid drugs. Adhering to the strategy of innovation and internationalization, explored the wide application of biotechnology in the field of general health, actively cultivated and incubated new industries, and is committed to becoming a leader in high- quality biopharmaceutics and serving global patients.

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein therapeutics and microecological agents. We focus on pharmaceutical research in the therapeutic fields of antiviral, oncology, immunology, hematology, digestion and degenerative diseases.It has built cutting-edge biotechnology platforms such as new proteins, new antibodies and nucleic acid drugs. Adhering to the strategy of innovation and internationalization, explored the wide application of biotechnology in the field of general health, actively cultivated and incubated new industries, and is committed to becoming a leader in high- quality biopharmaceutics and serving global patients.

Kexing Biopharm operates multiple R&D centers, such as the Shenzhen Medical Research Institute, the Shandong R&D Center and the Guangzhou R&D Center. It boasts an R&D team of nearly 200 members, with over 60% holding master's degrees or higher. At present, it has obtained 65 patents. The Company has established a complete drug R&D and innovation system with three major biotechnology systems: Prokaryotic cell technology, eukaryotic cell technology, and viable bacteria technology. Depending on these systems, it has built several leading technology platforms worldwide, such as KX-FUSION Fusion Protein Technology Platform, KX-BODY Antibody Technology Platform, K'Exosome Delivery Technology Platform, Vector Vaccine Technology Platform, and Microecological Agent R&D and Industrialization Technology Platform.

The Company focuses on biopharmaceuticals and implements a strategic R&D plan that enables a tiered, serial, and graduated product portfolio. Our short-term efforts are concentrated on in-depth development around new formulations, new indications and long-acting effects for recombinant protein therapeutics. In the medium and long term, we focus on fields such as oncology, immunology and degenerative diseases, with plans to develop new antibodies, proteins and nucleic acid drugs. It boasts robust pipelines of innovative drugs and dozens of projects currently under development, including GB05 Human Interferon α1b Inhalation Solution (Phase III clinical trial), GB-K02 Long-acting Human Granulocyte Colony-stimulating Factor Injection (Phase III clinical trial), GB08 Long-acting Growth Hormone (completed Phase I clinical trial), GB10 (target: VEGF/ANG-2) for fundus diseases, GB12 (target: IL-4R/IL-31(R)) for atopic dermatitis, GB18 (target: GDF-15) for cancer cachexia, GB23 (target: IFN/GPC3/PD1) for solid tumors, GB24 (target: TL1A, bispecific antibody) for inflammatory bowel diseases, and GB25 (tri-specific antibody) for colorectal cancer.

Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology and becoming the leader in high-quality biologics!